Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer
Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL
Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer
Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC
Cancer evasion of the immune system: the fundamentals
Checkpoint blockade: a concept or already a reality?
Myeloma genomics and Immuno-oncology
Novel targets and immune based therapy in myeloma
Upcoming trends in myeloma therapy
Lecture: Current standard of care in advanced disease
Lecture: Exploring the androgen signalling pathway in CRPC
Lecture: Clinical perspectives: Non-AR therapeutic targets in CRPC